Last updated: 2026-09-16 10:32:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Context Therapeutics Inc. (CNTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.35, with a market capitalisation of $32.25M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.34 to $3.62. This page covers its latest market performance, valuation, price trends and company information.
$32.25M | |
$0.37 | |
$10.87 | |
$0.34 | |
$0.36 | |
2.90K | |
2.63M | |
-- | |
$3.62 | |
$0.34 | |
-- | |
-- |
Context Therapeutics Inc. (CNTX) is trading at $0.35 in pre-market trading as of 2026-09-16 10:01:00, down 2.85% ($0.01) from the previous close of $0.36
Pre-market trading shows how investors are pricing CNTX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Context Therapeutics Inc. (CNTX) moved from $0.36 to $0.35, representing a decline of 2.13% ($0.01).
The stock traded between $0.34 and $0.38 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.10 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.3%
CNTX is currently trading at $0.35, placing it 0.3% of the way from its 52-week low of $0.34 to its 52-week high of $3.62. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 15 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Context Therapeutics Inc. (CNTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.